PMCB PharmaCyte Biotech, Inc. Insider Trading

Director Schechter buys 60,000 shares of PMCB in 3 tranches (Jan 5–7) at $0.78–$0.84, raising stake 45.3% to 192,500 shares amid stock at -54.1% from 52-week high

Jonathan Schechter, Director at PharmaCyte Biotech, purchased 60,000 shares (60.0K shares) across 3 separate transactions on January 5–7, 2026 at prices of $0.78, $0.79, and $0.84, for a blended average price of $0.80 and total investment of $48,232.00 ($48.2K). His holdings rose 45.3% from 132,500 shares to 192,500 shares post-transaction. This buy occurs as the stock trades at -54.1% from its 52-week high of $1.81, with a 30-day decline of -27.8%. However, context is important: Schechter's prior cross-ticker track record shows 3 prior buys with an average 90-day return of -31.8% and a 0.00% win rate over 90 days, suggesting that his historical purchasing decisions have not coincided with price appreciation. The company fundamentals are stressed, with zero revenue in the latest quarter and a net loss of $-7,417,975.00 ($-7.4M), reflected in a market cap of only $8,411,352.80 ($8.4M).

CEO Silverman purchases 100,000 shares (100.0K) across 3 trades at $0.78–$0.83 for $80,476.00 total amid -27.8% 30-day decline.

Joshua Silverman, CEO and President of PharmaCyte Biotech, executed 3 separate purchases totaling 100,000 shares for $80,476.00, raising his stake by 31.6% from 316,250 to 416,250 shares. The purchases occurred at prices ranging from $0.78 to $0.83, during a period when the stock has declined 27.8% over 30 days and trades 54.1% below its 52-week high of $1.81. The company is currently unprofitable (net income $-7,417,975.00) with zero quarterly revenue and a market cap of $8,411,352.80. The CEO's accumulation at declining prices, while the company faces significant operational headwinds, presents a pattern that merits scrutiny of both the business fundamentals and management's rationale for the deployment of capital at this valuation.